News
PLXP
--
0.00%
--
DJ PLx Pharma Shares Drop 11% After Public Offering Prices
Dow Jones · 2h ago
Ovid Therapeutics, KemPharm leads healthcare gainers; Vir Biotechnology, NanoViricides among major losers
Gainers: Ovid Therapeutics (OVID) +48%, KemPharm (KMPH) +46%, Ocugen (OCGN) +34%, Asensus Surgical (TRXC) +32%, Heat Biologics (HTBX) +16%.Losers: Vir Biotechnology (VIR) -29%, NanoViricides (NNVC) -16%, ASLAN Pharmaceuticals (ASLN) -11%, PLx Pharma (PLXP)...
Seekingalpha · 4h ago
PLx Pharma Prices $63 Million Share Offering at Discount; Stock Drops 12%
MT Newswires · 5h ago
DJ PLx Pharma Prices Public Offering of 7.9M Shares
Dow Jones · 5h ago
PLx Pharma under pressure after $63M capital raise
PLx Pharma (PLXP) drops 12% premarket after pricing public offering of ~7.9M common shares at $8.00/share.Expected gross proceeds are ~$63M.Underwriters' over-allotment is an additional ~1.2M shares. Net proceeds will be used for
Seekingalpha · 6h ago
PLx Pharma Prices $63M Underwritten Public Offering Of 7.875M Shares Of Common Stock At $8/Share
PLx Pharma Inc. Prices $63 Million Underwritten Public Offering of Common Stock SPARTA, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage
Benzinga · 6h ago
PLx Pharma Inc. Prices $63 Million Underwritten Public Offering of Common Stock
SPARTA, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to pr...
GlobeNewswire · 6h ago
Wall Street Mixed Midday as Bond Yields Tick Up Again
MT Newswires · 6h ago
Rocket Companies, Magnolia Oil & Gas leads the premarket losers' pack
Luokung Technology (LKCO) -11%.Magnolia Oil & Gas (MGY) -11% on pricing 17M shares in secondary offering.Stratasys (SSYS) -10% on pricing ~7M stock offering.PLx Pharma (PLXP) -9% after proposed capital raise.STRATA Skin Sciences (SSKN) -8%.NanoViricides (N...
Seekingalpha · 6h ago
8-K: PLx Pharma Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 14h ago
BRIEF-Plx Pharma Announces Proposed Public Offering Of Common Stock
reuters.com · 22h ago
PLx Pharma proposes capital raise
PLx Pharma (PLXP) announces that it intends to offer and sell shares in an underwritten public offering.Intends to grant the underwriters a 30-day option to purchase up to an additional
Seekingalpha · 22h ago
PLx Pharma Announces Proposed Public Offering of Common Stk >PLXP
PLx Pharma Announces Proposed Public Offering of Common Stk >PLXP
Dow Jones · 22h ago
PLx Pharma Inc. Announces Proposed Public Offering of Common Stock
SPARTA, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to pr...
GlobeNewswire · 23h ago
NIO, C3.ai leads the premarket losers' pack
FibroGen (FGEN) -25% on Q4 earnings release and after FDA to hold AdCom meet to review FibroGen, AstraZeneca's kidney drug.Comstock Mining (LODE) -19% after launching 4M-share public offering.Inseego (INSG) -16% on Q4 earnings release.RedHill Biopharma (RD...
Seekingalpha · 1d ago
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 1)
Benzinga · 1d ago
PLx Pharma Shares Trading Higher On FDA Approval For Newly Formulated Vazalore Dose
The FDA has approved PLx Pharma Inc's (NASDAQ: 
Benzinga · 2d ago
BRIEF-Plx Pharma Receives FDA Approval Of SNDAs For Both Vazalore 325 Mg And 81 Mg
reuters.com · 2d ago
Athenex, Xtant Medical among major healthcare premarket losers' pack
Athenex ATNX -55% on Q4 earnings release and on FDA rejection of oral paclitaxel application in breast cancer.Xtant Medical Holdings (XTNT) -16%.PLx Pharma PLXP -9% after FDA OKs PLx Pharma's Vazalore applications.Lixte Biotechnology Holdings (LIXT) -12%.A...
Seekingalpha · 2d ago
DJ PLx Pharma Gets FDA Approval of Vazalore Supplemental New Drug Applications
Dow Jones · 2d ago
Webull provides a variety of real-time PLXP stock news. You can receive the latest news about PLx Pharma through multiple platforms. This information may help you make smarter investment decisions.
About PLXP
PLx Pharma Inc. is a late-stage specialty pharmaceutical company. It is focusing on developing clinically-validated and patent-protected PLxGuard delivery system. Its lead product, Vazalore 325 mg, which is a formulation of aspirin using the PLxGuard delivery system intended to provide antiplatelet for cardiovascular disease prevention as compared to the current standard of care, enteric-coated aspirin, and significantly reduce gastric side effects. The Company has also developed Vazalore 81 mg, a lower-dose companion product for Vazalore 325 mg. The PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. Its product pipeline also includes other oral NSAIDs using the PLxGuard delivery system that may be developed, including a clinical-stage, GI-safer ibuprofen, PL1200 Ibuprofen 200 mg, for pain and inflammation.